Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Ag Ord (OP: BAYZF )

59.36 -1.79 (-2.92%)
Streaming Delayed Price Updated: 9:42 AM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,153
Open 59.57
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 61.15
Today's Range 59.36 - 59.57
52wk Range 45.99 - 74.34
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B
Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years. 
Via Benzinga
Bayer Bolsters Its Position In Digital Medical Imaging With Acquisition Of UK-Based Firm
 
Via Benzinga

Performance

YTD
+12.38%
+12.38%
1 Month
-4.26%
-4.26%
3 Month
+15.49%
+15.49%
6 Month
+26.11%
+26.11%
1 Year
-11.40%
-11.40%

More News

Read More
FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories
Via Benzinga
Activist Investor Builds Stake In Bayer, Pushes Breakup
Via Benzinga
Ionis Regains Rights To Thrombosis Candidate From Bayer
Via Benzinga
Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death
Via Benzinga
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
Via Benzinga
Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer's Favor
Via Benzinga
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report
Via Benzinga
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, June 10
Via Benzinga
US Top Court To Decide On Bayer's Roundup Weedkiller Appeal
Via Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
Via Benzinga
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Via Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Via Benzinga
Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities
Via Benzinga
Bayer's Nubeqa Shows Prolonged Survival In Late-Stage Prostate Cancer Trial
Via Benzinga
Microsoft, Bayer Collaborate To Develop Digital Agricultural Tools, Capabilities
Via Benzinga
Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration
Via Benzinga
Berkeley Lights, Bayer Ink Discovery Pact For Next-Gen Traits In Agricultural Sector, Berkeley Q2 Earnings Miss Estimates
Via Benzinga
Topics Earnings
Exposures Financial
Merck - Bayer's Heart Failure Treatment, Verquvo Scores European Nod
Via Benzinga
Bayer's Kerendia Scores Long-Awaited Kidney & Heart Disease Nod For Type 2 Diabetes
Via Benzinga
Exposures Product Safety
Why Did Novocure Shares Plunge Today?
Via Benzinga
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.